What is Scinai Immunotherapeutics Operating Cash Flow per Share?
Scinai Immunotherapeutics's operating cash flow per share for the
three
months ended in Sep. 2023 was $-0.47.
Scinai Immunotherapeutics's operating cash flow per share for the trailing twelve months (TTM) ended in Sep. 2023 was $-2.58.
During the past 3 years, the average Operating Cash Flow per Share Growth Rate was 47.90% per year.
During the past 5 years, the average Operating Cash Flow per Share Growth Rate was 17.50% per year.
During the past 10 years, the average Operating Cash Flow per Share Growth Rate was -5.90% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the OCF Growth Rate using Operating Cash Flow per Share data.
The historical rank and industry rank for Scinai Immunotherapeutics's Operating Cash Flow per Share or its related term are showing as below:
SCNI'
s 3-Year OCF Growth Rate Range Over the Past 10 Years
Min: -54.2 Med: -20.2 Max: 47.9
Current: 47.9
During the past 12 years, Scinai Immunotherapeutics's highest 3-Year average Operating Cash Flow per Share Growth Rate was 47.90% per year. The lowest was -54.20% per year. And the median was -20.20% per year.
SCNI's 3-Year OCF Growth Rate is ranked better than 90.25% of 1241
companies
in the Biotechnology industry
Industry Median: 3.7
vs SCNI: 47.90
Scinai Immunotherapeutics Operating Cash Flow per Share Historical Data
The historical data trend for Scinai Immunotherapeutics's Operating Cash Flow per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
Scinai Immunotherapeutics Operating Cash Flow per Share Chart
Competitive Comparison of Scinai Immunotherapeutics's Operating Cash Flow per Share
For the Biotechnology subindustry, Scinai Immunotherapeutics's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Scinai Immunotherapeutics's Price-to-Operating-Cash-Flow Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Scinai Immunotherapeutics's Price-to-Operating-Cash-Flow distribution charts can be found below:
* The bar in red indicates where Scinai Immunotherapeutics's Price-to-Operating-Cash-Flow falls into.
Scinai Immunotherapeutics Operating Cash Flow per Share Calculation
Operating Cash Flow per Share is the amount of Cash Flow from Operations per outstanding share of the company's stock.
Scinai Immunotherapeutics's Operating Cash Flow per Share for the fiscal year that ended in Dec. 2022 is calculated as
Operating Cash Flow per Share for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.58
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Scinai Immunotherapeutics Operating Cash Flow per Share Related Terms
Thank you for viewing the detailed overview of Scinai Immunotherapeutics's Operating Cash Flow per Share provided by GuruFocus.com. Please click on the following links to see related term pages.
Scinai Immunotherapeutics (Scinai Immunotherapeutics) Business Description
BiondVax Pharmaceuticals Ltd is a biopharmaceutical company focused on developing, manufacturing and commercializing innovative products for the prevention and treatment of infectious diseases and other illnesses. It has executed eight clinical trials in seven countries, around 12,400 participants in the Phase 3 trial of its vaccine candidate and has built a GMP biologics manufacturing facility for biopharmaceutical products. The company is aiming to develop a pipeline of diversified and commercially viable products and platforms beginning with an innovative nanosized antibody (NanoAb) pipeline.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
SCNI has been successfully added to your 